Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Flexcel** is a Prisure Medicare marketed oral tablet brand family rather than one uniquely defined drug substance. The family includes **Flexcel-60** containing etoricoxib 60 mg, **Flexcel-90** containing etoricoxib 90 mg, and **Flexcel-ETH-4** containing etoricoxib 60 mg plus thiocolchicoside 4 mg. Etoricoxib is a selective cyclooxygenase-2 inhibitor used for pain and inflammation; the ETH-4 formulation additionally includes the centrally acting muscle relaxant thiocolchicoside for painful musculoskeletal spasm. Because the unqualified name does not specify which formulation is intended, it cannot be assigned one exact active-ingredient composition or mechanism. ([prisuremedicare.com](https://prisuremedicare.com/products.html))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Flexcel.